Loading...

Bristol-Myers Squibb Company

BMYNYSE
Healthcare
Drug Manufacturers - General
$48.43
$-0.51(-1.04%)

Bristol-Myers Squibb Company (BMY) Stock Overview

Explore Bristol-Myers Squibb Company’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 77.9/100

Key Financials

Market Cap98.6B
P/E Ratio18.10
EPS (TTM)$2.68
ROE0.32%
Fundamental Analysis

AI Price Forecasts

1 Week$48.76
1 Month$48.05
3 Months$57.05
1 Year Target$42.06

BMY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Bristol-Myers Squibb Company (BMY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 54.23, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $42.06.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 18.10 and a market capitalization of 98.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;